Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6397MR)

This product GTTS-WQ6397MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6397MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4926MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ4123MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ10069MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ8427MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ791MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ3112MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ11094MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ4839MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW